Self‑report questionnaire to spot inherited cancer risk in children and teens
Official title: Questionnaire on Congenital Cancer Signs Through Self-Assessment (QUOCCAS)
Run by Insel Gruppe AG, University Hospital Bern · NCT07378423 · Data updated 2026-11-12
This project will test whether a caregiver- or patient-completed questionnaire plus a short pre-visit brochure can help identify children and adolescents with an inherited cancer predisposition and improve caregiver genetics knowledge and satisfaction.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 21 Years |
| Sex | All |
| Enrollment | 205 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07378423 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents under age 21 with a newly diagnosed cancer included in ICCC3 who are treated at the participating University Children’s Hospital Bern.
✕Probably not a fit
Patients older than 21, those whose diagnosis is not covered by ICCC3, or those already known to have a genetic cancer predisposition are unlikely to benefit from this enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Newly diagnosed children and adolescents treated at the University Children’s Hospital Bern will complete the QUOCCAS questionnaire about family history and cancer signs and provide a blood or saliva sample for germline sequencing (whole-exome or whole-genome). Families will be randomly assigned to receive a Pre-Visit Preparation (PVP) brochure or not before their clinic visit to measure effects on caregiver genetics knowledge and satisfaction. The QUOCCAS results will be compared with physician-based tools (including MIPOGG) and with germline genetic testing to determine how well the questionnaire flags potential cancer predisposition syndromes. Study outcomes include the questionnaire’s accuracy against sequencing and changes in caregiver understanding and satisfaction.
Why it matters
Potential benefit: If successful, this approach could help identify children with inherited cancer risk earlier, enabling targeted surveillance, tailored care, and cascade testing for family members.
How similar studies have gone: Clinician checklists and family-history tools have shown promise in identifying some cancer predisposition syndromes, but direct comparisons with comprehensive germline sequencing and the addition of pre-visit education remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The investigators will include newly diagnosed patients who received a cancer diagnosis included in the International Classification of Childhood Cancer version 3 (ICCC3) criteria, treated at participating hospitals Exclusion Criteria: * Over 21 years of age
Where it's running
-
Inselspital, Universitäts Kinderklinik (University Children's Hospital) Bern
Bern, Switzerland Recruiting
Study contacts
- Principal investigator: Nicolas Waespe, MD PhD, PD — University Children's Hospital Bern, Inselspital, Bern, Switzerland
- Study coordinator: Nicolas Waespe, MD PhD, PD
- Email: quoccas@insel.ch
- Phone: +41 77 435 37 95
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FaceSay: a computer program to help kids recognize facial expressions and improve social interactions
A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.
-
AI chatbot to screen for hereditary cancer risk in Singaporeans
A chat-based AI tool is being tested to see if it can quickly and reliably flag people who may have hereditary cancer risk.
-
Access to Innovative Cancer Treatments for Children and Young People in Belgium
This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children
This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.